Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled medicines for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Its pipeline centers on reformulating proven oral antifibrotics as inhaled therapies—such as AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib)—to deliver drug directly to lung tissue and potentially reduce systemic side effects. The company targets patients who need better-tolerated options than current systemic treatments for progressive lung scarring.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -17.5 | — |
| Q1 2026 | 0 | — | -26.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: MillerKnoll, Inc. (MLKN), Xeris Biopharma Holdings, Inc. (XERS), Phibro Animal Health Corporation (PAHC), Tandem Diabetes Care, Inc. (TNDM), SL Science Holding Limited (SLBT), Bicara Therapeutics Inc. (BCAX)